Life Science VC Firm Launches Quell with $43 Million Series A Round

On 5/20/19 Syncona Ltd ("Syncona") announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35 million ($43 million) commitment in a Series A financing of which Syncona has committed £34.0 million with a further £1.0 million being contributed by UCL Technology Fund. Syncona will have a 69.3 per cent stake1 in the business, with the first tranche of the Series A commitment of £8.3m paid in March 2019.